MiNK Therapeutics, Inc. Annual Report: A Simple Guide

I’ve put together this guide to help you understand how MiNK Therapeutics performed this year. Instead of digging through dense financial filings, we’ll break down the key facts so you can decide if this company fits your investment goals.

1. What does this company do?

MiNK is a clinical-stage biotech company. They develop "off-the-shelf" cell therapies using invariant Natural Killer T (iNKT) cells.

These cells combine the rapid-response power of Natural Killer cells with the long-term memory of T-cells. Their goal is to create treatments for cancer and severe lung inflammation that can be used immediately. Unlike older therapies that take weeks to produce and cost over $400,000 per patient, MiNK’s approach aims to be faster and more accessible.

2. Financial performance

MiNK is currently spending more than it earns. For the year ending December 31, 2024, the company lost $22.4 million, an improvement over the $25.8 million loss in 2023.

As of year-end 2024, they held about $7.2 million in cash. With a quarterly spending rate of $5 million to $6 million, their cash runway is short. They will need to raise more money soon, which often means issuing more shares and reducing your ownership percentage.

3. Major wins and progress this year

The company made promising strides in their clinical trials:

• Respiratory Success: Their lead program, agenT-797, showed strong results in patients with severe viral pneumonia. In 2024, 70% of patients on ventilators survived, compared to a typical survival rate of 10% to 20% in similar groups.
• Cancer Results: In early trials for solid tumors, patients with gastric and testicular cancers saw their disease stabilize or shrink for over six months.
• New Tech: They are developing new "armored" therapies, MiNK-215 and MiNK-413, and aim to start formal testing for these by late 2025.

4. The "Red Flag" (Nasdaq Listing)

The biggest hurdle is their standing with the Nasdaq. In May 2025, they received a notice that their market value fell below the $35 million minimum required to stay listed. If they cannot keep their value above this threshold for 10 straight business days, they face delisting. Delisting would make it much harder for investors to trade the stock and could limit the company’s access to cash.

5. Key risks for investors

• Cash Flow: Their $7.2 million in cash won't last through 2026. They must find new funding or strike a partnership deal to keep trials running.
• Nasdaq Listing: Delisting could cause the share price to drop and limit access to capital.
• Clinical Success: Biotech is high-risk. If larger trials don't match early results, the company’s value could collapse.
• Competition: They face well-funded rivals like Fate Therapeutics and Allogene Therapeutics.
• Related Party Dependency: Agenus Inc. provides much of MiNK’s support. If Agenus struggles, MiNK’s operations could suffer.

6. Future outlook

MiNK is focused on surviving the "development gap." They are pushing to get their lead drug into larger trials to attract a potential buyer or partner. They are also working to lower their manufacturing costs. They continue to rely on their partnership with Agenus Inc., their largest shareholder, to keep their research moving toward a commercial product.

Investor Takeaway: MiNK is a high-stakes play. The clinical data for agenT-797 is encouraging, but the company is in a race against time. With limited cash and a looming Nasdaq delisting, the primary question for any investor is whether the company can secure a partnership or funding round before their current resources run dry.